Generation Bio, a biotechnology company that is innovating genetic medicines for people living with rare and prevalent diseases, announced on Monday that it will participate in the 22nd Annual Needham Virtual Healthcare Conference. On Tuesday, April 18th at 3 p.m. EST, Geoff McDonough, M.D., president and CEO of the company, will participate in a fireside chat.
The live webcast of the panel will be available on the investor section of the Generation Bio website at investors.generationbio.com. The replay will be available there for 30 days following the event. The annual conferences offer opportunities for companies to showcase their businesses, to discuss industry trends, and to network with other healthcare professionals.
Also Read:
A Breakdown Of Power Tool Brushes Market Segmentaion from 2023 to 2030 with a projected CAGR of 4.8%
Generation Bio is driving innovation in genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company is developing a non-viral genetic medicine platform that incorporates a novel DNA construct called closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a highly scalable capsid-free manufacturing process that uses a proprietary cell-free rapid enzymatic synthesis (RES) to produce the antibiotic-resistant DNA required for such gene therapy.
This approach is intended to allow for multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues and cell types, and to allow titration and redosing to adjust or extend expression levels in each patient.
Also Read:
Generation Bio’s manufacturing scale, which is powered by RES, has the potential to expand to hundreds of millions of doses to support its mission to extend genetic medicine to more people living with rare and prevalent diseases around the world. With its innovative platform, the company is poised to make inroads in helping individuals with genetic diseases that have few, if any, treatment options.
McDonough, who will be presenting on Tuesday, has a track record in the biotech industry, where he has been instrumental in advancing promising drug development programs that ultimately achieved significant commercial success. Prior to joining Generation Bio, he was President and CEO of Swedish Orphan Biovitrum (Sobi), a rare disease biotechnology company, where he led a corporate transformation and oversaw the successful in-licensing and commercialization of several blockbuster therapies.
Also Read:
As the world continues to grapple with a host of rare and prevalent diseases, Generation Bio’s mission to bring genetic medicine to more people is more urgent than ever. The company’s participation in the 22nd Annual Needham Virtual Healthcare Conference will provide an opportunity for Generation Bio to highlight its innovative platform, gain exposure to a wider audience of healthcare professionals, and attract investment to support the development of new therapies.
In Other News Around the World:
A Breakdown Of Power Tool Brushes Market Segmentaion from 2023 to 2030 with a projected CAGR of 4.8%